ChengDu ShengNuo Biotec Co.,Ltd.

688117

CNE1000051M8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
23.88 ^CNY	+7.52%		+2.93%	-15.32%

05-07	Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection	MT
04-22	ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

GermanLitho announced that it has received funding from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.), ChengDu ShengNuo Biotec Co.,Ltd.

September 15, 2022

GermanLitho announced that it has received funding on September 16, 2022. The transaction included participation from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.) and ChengDu ShengNuo Biotec Co.,Ltd.

Latest news about ChengDu ShengNuo Biotec Co.,Ltd.

Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection	05-07	MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Cheng Du Sheng Nuo Biotec Completes US FDA Filing For Constipation Drug API	11-15	MT
Biocells Biotechnology Co., Ltd. announced that it has received funding from ChengDu ShengNuo Biotec Co.,Ltd., Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd., Green Pine Capital Partners Co., Ltd.	30/10/23	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
ChengDu ShengNuo Biotec Co.,Ltd. cancelled the transaction announced on May 16, 2023	19/10/23	CI
Sheng Nuo Biotec's Unit Gets Nod to Amend Usage of Carbetocin Injection	07/09/23	MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	16/08/23	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/02/23	CI
Three Cheng Du Sheng Nuo Biotec Execs to Divest Stakes	04/11/22	MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
GermanLitho announced that it has received funding from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.), ChengDu ShengNuo Biotec Co.,Ltd.	15/09/22	CI
WNL Biomedtech announced that it has received funding from Huaying Capital, ChengDu ShengNuo Biotec Co.,Ltd.	15/09/22	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange Composite Index	03/06/22	CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange A Share Index	03/06/22	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22	CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/10/21	CI
Meishan Huilong Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from ChengDu ShengNuo Biotec Co.,Ltd.	11/07/21	CI

Chart ChengDu ShengNuo Biotec Co.,Ltd.

Duration

Period

More charts

Company Profile

ChengDu Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The Company's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The Company mainly conducts its business in domestic and foreign markets.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ChengDu ShengNuo Biotec Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.88 CNY

Average target price

38 CNY

Spread / Average Target

+59.13%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHENGDU SHENGNUO BIOTEC CO.,LTD.	-15.32%	343M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.78%	43.29B
OTSUKA HOLDINGS CO., LTD.	+27.64%	22.38B
SANDOZ GROUP AG	+19.25%	15.51B
CIPLA LIMITED	+18.68%	14.52B
ZYDUS LIFESCIENCES LIMITED	+54.64%	12.93B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.39%	6.56B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.62%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals

ChengDu ShengNuo Biotec Co.,Ltd.

Equities

688117

CNE1000051M8

Pharmaceuticals

GermanLitho announced that it has received funding from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.), ChengDu ShengNuo Biotec Co.,Ltd.

Latest news about ChengDu ShengNuo Biotec Co.,Ltd.

Chart ChengDu ShengNuo Biotec Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for ChengDu ShengNuo Biotec Co.,Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals